SERA PROGNOSTICS, INC. (SERA) Free cash flow
- Free cash flow · 12 months (USD): Value $-28.15M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -40211.43%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-28.15M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-27.68M − $466.00K ≈ $-28.15M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -40211.43% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-28.15M ÷ $70.00K × 100 ≈ -40211.43% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-27.68M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.83× | Operating cash flow / net income. Period ending 2026-06-30. $-27.68M ÷ $-33.23M ≈ 0.83× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -27.68M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 466.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -28.15M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 70.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | -33.23M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-28.15M | (m) | $-27.68M | $466.00K | (m) | $70.00K | (m) | $-33.23M | (m) | (m) | -40211.43% | 0.83× |
| 2026-03-31 | $-27.57M | (m) | $-26.84M | $731.00K | (m) | $57.00K | (m) | $-32.14M | (m) | (m) | -48377.19% | 0.84× |
| 2025-12-31 | $-26.35M | (m) | $-25.62M | $726.00K | (m) | $81.00K | (m) | $-31.93M | (m) | (m) | -32529.63% | 0.80× |
| 2025-09-30 | $-26.17M | (m) | $-25.76M | $404.00K | (m) | $95.00K | (m) | $-32.63M | (m) | (m) | -27544.21% | 0.79× |
| 2025-06-30 | $-26.60M | (m) | $-26.28M | $318.00K | (m) | $108.00K | (m) | $-32.73M | (m) | (m) | -24628.70% | 0.80× |
| 2025-03-31 | $-26.78M | (m) | $-26.74M | $44.00K | (m) | $115.00K | (m) | $-32.99M | (m) | (m) | -23286.96% | 0.81× |
| 2024-12-31 | $-14.24M | (m) | $-14.19M | $56.00K | (m) | $77.00K | (m) | $-32.90M | (m) | (m) | -18500.00% | 0.43× |
| 2024-09-30 | $-14.76M | (m) | $-14.69M | $64.00K | (m) | $94.00K | (m) | $-32.24M | (m) | (m) | -15700.00% | 0.46× |
| 2024-06-30 | $-15.36M | (m) | $-15.29M | $64.00K | (m) | $107.00K | (m) | $-31.54M | (m) | (m) | -14352.34% | 0.48× |
| 2024-03-31 | $-17.42M | (m) | $-17.31M | $104.00K | (m) | $206.00K | (m) | $-33.77M | (m) | (m) | -8454.85% | 0.51× |
| 2023-12-31 | $-27.32M | (m) | $-27.19M | $128.00K | (m) | $306.00K | (m) | $-36.24M | (m) | (m) | -8926.80% | 0.75× |
| 2023-09-30 | $-27.97M | (m) | $-27.66M | $305.00K | (m) | $330.00K | (m) | $-38.06M | (m) | (m) | -8474.55% | 0.73× |
| 2023-06-30 | $-29.50M | (m) | $-28.84M | $651.00K | (m) | $375.00K | (m) | $-41.56M | (m) | (m) | -7865.33% | 0.69× |
| 2023-03-31 | $-30.76M | (m) | $-29.93M | $823.00K | (m) | $330.00K | (m) | $-42.54M | (m) | (m) | -9320.30% | 0.70× |
| 2022-12-31 | $-35.40M | (m) | $-34.61M | $791.00K | (m) | $268.00K | (m) | $-44.19M | (m) | (m) | -13209.33% | 0.78× |
| 2022-09-30 | $-37.87M | (m) | $-36.52M | $1.35M | (m) | $229.00K | (m) | $-46.92M | (m) | (m) | -16537.55% | 0.78× |
| 2022-06-30 | $-38.45M | (m) | $-37.04M | $1.40M | (m) | $165.00K | (m) | $-46.07M | (m) | (m) | -23301.21% | 0.80× |
| 2022-03-31 | $-35.51M | (m) | $-34.24M | $1.27M | (m) | $107.00K | (m) | $-40.86M | (m) | (m) | -33189.72% | 0.84× |
| 2021-12-31 | $-32.94M | (m) | $-31.64M | $1.30M | (m) | $82.00K | (m) | $-35.01M | (m) | (m) | -40170.73% | 0.90× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-21.51M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-17.02M | (m) | $-16.87M | $149.00K | (m) | $25.00K | (m) | $-19.85M | (m) | (m) | -68068.00% | 0.85× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |